In this study, we investigated the value of alterated glycosylation of Hp as a diagnostic glycobiomarker for early detection of HCC in a panel of patients with liver diseases (as controls), and in cases of early- and late-stage HCC. This evidence concerns the gene HP and hepatocellular carcinoma.